In addition to immunization programs, antiviral agents can play a major role for the control of
seasonal influenza epidemics and may also provide prophylactic and therapeutic benefits …

In the current COVID-19 pandemic context, proposing and validating effective treatments
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …

We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory
syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral …

IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19
pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring …

In response to the current pandemic caused by the novel SARS-CoV-2, identifying and
validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro …

Background. Neuraminidase inhibitors (NAIs) play a key role in the management of influenza
epidemics and pandemics. Given the novel pandemic influenza A(H1N1) (pH1N1) virus …

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by
binding of the viral Spike protein to host receptor angiotensin-converting enzyme 2 (ACE2), …

Influenza viruses still constitute a real public health problem today. To cope with the emergence
of new circulating strains, but also the emergence of resistant strains to classic antivirals, …

Influenza viruses are major human pathogens with a global distribution, accounting for more
than 500,000 annual deaths worldwide and with considerable impact on the quality of life …